New Vaccine May Prevent Cancer: It can be said as a break through in medical industry, as a new study conducted on mice cured the cancer cells just through an injection. Eventually, it destroyed cancer cells not only where the vaccine was injected but also far from the injection point. The study found that this approach works for many different types of cancers, including those that arise spontaneously.
“This approach bypasses the need to identify tumour-specific immune targets and doesn’t require wholesale activation of the immune system or customisation of a patient’s immune cells”. One of the injections is already approved for human use, whilst the other is now in clinical trials for unrelated conditions. A clinical trial was launched in January to test the effect of the treatment in patients with lymphoma.
The vaccine exploits a peculiarity of the immune system. Others target naturally occurring checkpoints that limit the anti-cancer activity of immune cells. The new vaccine works by reactivating these T cells. This compound is a combination of two agents. “In the mice, we saw awesome, bodywide effects, including the elimination of tumors all over the animal”.
The researchers said that, We’re attacking specific targets without having to identify exactly what proteins the T cells are recognizing. One of the two agents, called CpG oligonucleotide, together with other immune cells, intensifies the T-cells’ activating receptors called OX40. Then, the other agent activates the T-cell to fight cancer cells.
The researchers published their findings this week in the academic journal Science Translational Medicine, claiming to have “developed a practical strategy for immunotherapy of cancer”. Instructor of medicine Idit Sagiv-Barfi, PhD, is the lead author.
The cancer vaccine was also tested on mice models of breast cancer. Cancer recurrence happens when cancer returns after treatment. The T-cells contained in the two agents had worn off the jab tumor in the 87 out of the 90 mice. Still, the study confirms that its possible to treat cancer without the need to genetically engineer cells outside the body or extract its RNA to be injected back again while applying electric charges. For the trial, Levy plans to recruit 15 patients with low-grade lymphoma.
For More Latest Updates: Follow PressKS